Odyssey Therapeutics (NASDAQ:ODTX) Now Covered by Analysts at HC Wainwright

HC Wainwright assumed coverage on shares of Odyssey Therapeutics (NASDAQ:ODTX) in a research report released on Friday morning, MarketBeat reports. The firm issued a buy rating and a $40.00 target price on the stock. HC Wainwright also issued estimates for Odyssey Therapeutics’ Q1 2027 earnings at ($1.27) EPS, Q2 2027 earnings at ($1.29) EPS, Q3 2027 earnings at ($1.29) EPS and Q4 2027 earnings at ($1.28) EPS.

Other equities analysts have also issued research reports about the stock. JPMorgan Chase & Co. lifted their price target on shares of Odyssey Therapeutics from $26.00 to $29.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. Raymond James Financial began coverage on shares of Odyssey Therapeutics in a report on Thursday, October 8th. They issued an “outperform” rating and a $42.00 target price on the stock. UBS Group initiated coverage on shares of Odyssey Therapeutics in a research report on Monday, October 12th. They set a “buy” rating and a $27.00 target price for the company. Finally, Weiss Ratings started coverage on shares of Odyssey Therapeutics in a report on Tuesday, August 11th. They set a “sell (d+)” rating for the company. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $34.67.

Odyssey Therapeutics Stock Up 1.9%

Shares of Odyssey Therapeutics stock traded up $0.35 during trading on Friday, hitting $19.23. The stock had a trading volume of 577,256 shares, compared to its average volume of 248,226. The stock’s 50 day simple moving average is $21.18. The stock has a market cap of $924.19 million and a P/E ratio of -2.84. Odyssey Therapeutics has a 1 year low of $15.10 and a 1 year high of $29.05.

Odyssey Therapeutics (NASDAQ:ODTX) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($1.74) earnings per share (EPS) for the quarter. On average, sell-side analysts predict that Odyssey Therapeutics will post -6.08 earnings per share for the current year.

Institutional Investors Weigh In On Odyssey Therapeutics

Institutional investors have recently bought and sold shares of the business. State Street Corp bought a new position in shares of Odyssey Therapeutics during the 2nd quarter worth about $1,477,000. Citadel Advisors LLC bought a new stake in Odyssey Therapeutics in the second quarter valued at about $4,162,000. The Manufacturers Life Insurance Company acquired a new position in Odyssey Therapeutics in the second quarter worth about $601,000. Russell Investments Group Ltd. acquired a new position in Odyssey Therapeutics in the third quarter worth about $28,000. Finally, Aberdeen Group plc raised its position in Odyssey Therapeutics by 4.7% in the third quarter. Aberdeen Group plc now owns 172,771 shares of the company’s stock worth $3,839,000 after purchasing an additional 7,771 shares in the last quarter.

About Odyssey Therapeutics

Odyssey Therapeutics is a clinical-stage biotechnology company focused on discovering and developing precision medicines for immune-mediated diseases and cancer. The company combines computational biology, functional genomics, and experimental drug discovery to identify therapies directed at disease-driving biological pathways.

Its research programs are centered primarily on small-molecule medicines and other targeted approaches intended to modulate the immune system or address vulnerabilities in cancer cells.